Citius Oncology financials
$1.05+1.94%
Close Sep 29, 2026 · split-adjustedRevenue
Net income
Income statement & cash flow
| Quarter | Q3 '26 Jun 30 | Q2 '26 Mar 31 | Q1 '26 Dec 31 | Q4 '25 Sep 30 | Q3 '25 Jun 30 | Q2 '25 Mar 31 | Q1 '25 Dec 31 | Q4 '24 Sep 30 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $1.5M | $1.7M | $3.9M | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Gross profit | $1.0M | $1.3M | $3.2M | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Gross margin | 67.1% | 80.3% | 80.0% | — | — | — | — | — |
| Operating income | -$8.7M | -$28.6M | -$5.3M | -$4.7M | -$4.9M | -$7.5M | -$6.4M | -$6.7M |
| Net income | -$8.9M | -$26.6M | -$5.5M | -$5.0M | -$5.4M | -$7.7M | -$6.7M | -$6.8M |
| Net margin | −597.4% | −1596.0% | −140.3% | — | — | — | — | — |
| Diluted EPS | $-0.08 | $-0.27 | $-0.06 | $-0.06 | $-0.08 | $-0.11 | $-0.09 | $-0.10 |
| EBITDA | -$8.7M | -$29.2M | -$4.7M | -$4.7M | -$4.9M | -$7.5M | -$6.4M | -$6.7M |
| Operating cash flow | -$2.7M | -$3.8M | -$7.4M | -$5.5M | $0.00 | $0.00 | $0.00 | $126.4K |
| Free cash flow | -$2.7M | -$3.8M | -$7.4M | -$5.5M | $0.00 | $0.00 | $0.00 | $126.4K |
| Diluted shares | 107.9M | 100.0M | 87.5M | 78.4M | 71.6M | 71.6M | 71.6M | 69.7M |
Balance sheet
| Period end | Jun 30 | Mar 31 | Dec 31 | Sep 30 | Jun 30 | Mar 31 |
|---|---|---|---|---|---|---|
| Cash & equivalents | $16.6M | $2.6M | $7.3M | $3.9M | $112.00 | $112.00 |
| Short-term investments | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Total debt | $6.4M | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Total assets | $112.1M | $100.7M | $110.0M | $100.9M | $91.7M | $91.4M |
| Total liabilities | $71.7M | $65.4M | $51.6M | $56.1M | $59.3M | $55.8M |
| Shareholders' equity | $40.4M | $35.3M | $58.4M | $44.9M | $32.4M | $35.6M |
From SEC filings via Massive. Fiscal periods follow the company's own calendar; free cash flow is operating cash flow minus capital expenditure.
Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology